Transdermal patches for site-specific delivery of anastrozole: In vitro and local tissue disposition evaluation

International Journal of Pharmaceutics

Volumn 391, Issue 1-2, 2010, Pages 73-78

  Xi, Honglei ^a   Yang, Yonggang ^b   Zhao, Dongmei ^a   Fang, Liang ^a   Sun, Lin ^a   Mu, Liwei ^a   Liu, Jie ^a   Zhao, Nanxi ^a   Zhao, Yanyan ^a   Zheng, Ni ^a   He, Zhonggui ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Anastrozole; Local tissue disposition; Site specific drug delivery; Transdermal patch

Indexed keywords

ADHESIVE AGENT; ANASTROZOLE; PENETRATION ENHANCING AGENT; POLYESTER;

ABDOMEN; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG FORMULATION; DRUG MUSCLE LEVEL; DRUG PENETRATION; DRUG STRUCTURE; DRUG TISSUE LEVEL; FEMALE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SKIN; SKIN PERMEABILITY; TRANSDERMAL PATCH;

ADHESIVES; ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; MICE; MICE, INBRED STRAINS; NITRILES; PERMEABILITY; RATS; RATS, WISTAR; SKIN; SKIN ABSORPTION; TISSUE DISTRIBUTION; TRIAZOLES;

EID: 77952885361     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2010.02.021     Document Type: Article

References (30)

1. AstraZeneca Canada Inc., 2008. Product monograph: ARIMIDEX®. [Online] Available at: (). Accessed on 9.9.08. http://www.astrazeneca.ca/documents/ProductPortfolio/ARIMIDEX_PM_en.pdf.
2. Barry B.W. Is transdermal drug delivery research still important today?. Drug Discov. Today 2001, 6:967-971.
3. Brodie A., Long B., Lu Q. Aromatase expression in the human breast. Breast Cancer Res. Treat. 1998, 49(Suppl. 1):S85-S91. (discussion S109-119).
4. Brueggemeier R.W., Hackett J.C., Diaz-Cruz E.S. Aromatase inhibitors in the treatment of breast cancer. Endocr. Rev. 2005, 26:331-345.
5. Bulun S.E., Chen D., Lu M., Zhao H., Cheng Y., Demura M., Yilmaz B., Martin R., Utsunomiya H., Thung S., Su E., Marsh E., Hakim A., Yin P., Ishikawa H., Amin S., Imir G., Gurates B., Attar E., Reierstad S., Innes J., Lin Z. Aromatase excess in cancers of breast, endometrium and ovary. J. Steroid Biochem. Mol. Biol. 2007, 106:81-96.
6. Geisler J., Detre S., Berntsen H., Ottestad L., Lindtjorn B., Dowsett M., Lonning P.E. Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer. Clin. Cancer Res. 2001, 7:1230-1236.
7. Geisler J., King N., Dowsett M., Ottestad L., Lundgren S., Walton P., Kormeset P.O., Lonning P.E. Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br. J. Cancer 1996, 74:1286-1291.
8. Goss P., Wu M. Application of aromatase inhibitors in endocrine responsive breast cancers. Breast 2007, 16(Suppl. 2):S114-S119.
9. Harrison J.E., Watkinson A.C., Green D.M., Hadgraft J., Brain K. The relative effect of Azone and Transcutol on permeant diffusivity and solubility in human stratum corneum. Pharm. Res. 1996, 13:542-546.
10. He N., Warner K.S., Chantasart D., Shaker D.S., Higuchi W.I., Li S.K. Mechanistic study of chemical skin permeation enhancers with different polar and lipophilic functional groups. J. Pharm. Sci. 2004, 93:1415-1430.
11. Ibrahim S.A., Li S.K. Effects of chemical enhancers on human epidermal membrane: Structure-enhancement relationship based on maximum enhancement (E(max)). J. Pharm. Sci. 2009, 98:926-944.
12. Mendes G.D., Hamamoto D., Ilha J., Pereira Ados S., De Nucci G. Anastrozole quantification in human plasma by high-performance liquid chromatography coupled to photospray tandem mass spectrometry applied to pharmacokinetic studies. J. Chromatogr. B. 2007, 850:553-559.
13. Miki Y., Suzuki T., Sasano H. Aromatase inhibitor and bone. Biomed. Pharmacother. 2007, 61:540-542.
14. Mom C.H., Buijs C., Willemse P.H., Mourits M.J., De Vries E.G. Hot flushes in breast cancer patients. Crit. Rev. Oncol. Hematol. 2006, 57:63-77.
15. Mura P., Faucci M.T., Bramanti G., Corti P. Evaluation of transcutol as a clonazepam transdermal permeation enhancer from hydrophilic gel formulations. Eur. J. Pharm. Sci. 2000, 9:365-372.
16. Ouano A.C., Tu X.O., Carothers J.A. Dynamics of polymer dissolution. Structure Solubility Relationships in Polymers 1977, 11-20. Academic Press, New York. F.W. Harish, R.B. Seymour (Eds.).
17. Pfister W.R., Hsieh D.S. Permeation enhancers compatible with transdermal drug delivery systems. Part II. System design considerations. Med. Device Technol. 1990, 1:28-33.
18. Rao P.R., Reddy M.N., Ramakrishna S., Diwan P.V. Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits. Eur. J. Pharm. Biopharm. 2003, 56:81-85.
19. Santner S.J., Feil P.D., Santen R.J. In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab. 1984, 59:29-33.
20. Sarkar K., Yang H. Encapsulation and extended release of anti-cancer anastrozole by stealth nanoparticles. Drug Deliv. 2008, 15:343-346.
21. Suzuki T., Moriya T., Ishida T., Ohuchi N., Sasano H. Intracrine mechanism of estrogen synthesis in breast cancer. Biomed. Pharmacother. 2003, 57:460-462.
22. Tamulevicius P., Streffer C. Metabolic imaging in tumours by means of bioluminescence. Br. J. Cancer 1995, 72:1102-1112.
23. Tan H.S., Pfister W.R. Pressure-sensitive adhesives for transdermal drug delivery systems. Pharm. Sci. Technol. Today 1999, 2:60-69.
24. Tilson-Mallett N., Santner S.J., Feil P.D., Santen R.J. Biological significance of aromatase activity in human breast tumors. J. Clin. Endocrinol. Metab. 1983, 57:1125-1128.
25. Trommer H., Neubert R.H. Overcoming the stratum corneum: the modulation of skin penetration. A review. Skin Pharmacol. Physiol. 2006, 19:106-121.
26. Wilkinson K. Anastrozole (Arimidex). Clin. J. Oncol. Nurs. 2004, 8:87-88.
27. Williams A.C., Barry B.W. Penetration enhancers. Adv. Drug Deliv. Rev. 2004, 56:603-618.
28. Ye J.C., Zeng S., Zheng G.L., Chen G.S. Pharmacokinetics of Huperzine A after transdermal and oral administration in beagle dogs. Int. J. Pharm. 2008, 356:187-192.
29. Zhao L., Li Y., Fang L., He Z., Liu X., Wang L., Xu Y., Ren C. Transdermal delivery of tolterodine by O-acylmenthol: In vitro/in vivo correlation. Int. J. Pharm. 2009, 374:73-81.
30. Zidan A.S., Sammour O.A., Hammad M.A., Megrab N.A., Hussain M.D., Khan M.A., Habib M.J. Formulation of anastrozole microparticles as biodegradable anticancer drug carriers. AAPS PharmSciTech 2006, 7:61.